Identification

Name
Dimenhydrinate
Accession Number
DB00985  (APRD00924)
Type
Small Molecule
Groups
Approved
Description

Dimenhydrinate (Dramamine, Gravol and Vertirosan) is an over-the-counter drug used to prevent motion sickness. It is closely related to diphenhydramine HCl, or Benadryl. It is primarily a H1-antagonist, but also possesses an antimuscarinic effect.

Structure
Thumb
Synonyms
  • (O-Benzhydryl(dimethylamino)ethanol) 8-chlorotheophyllinate
  • 8-chloro-1,3-Dimethyl-3,7-dihydro-1H-purine-2,6-dione - 2-(diphenylmethoxy)-N,N-dimethylethanamine (1:1)
  • Benzhydryl-beta-dimethylaminoethylether 8-chlorotheophylline
  • beta-Dimethylaminoethyl benzhydryl ether 1,3-dimethyl-8-chloroxanthine
  • Dimenhidrinato
  • Dimenhydrinatum
  • Diphenhydramine 8-chlorotheophyllinate
  • Diphenhydramine 8-chlorotheophylline
  • Diphenhydramine theoclate
  • Diphenhydrinate
  • N,N-Dimethyl-2-diphenylmethoxyethylamine 8-chlorotheophyllinate
  • O-Benzhydryldimethylaminoethanol 8-chlorotheophyllinate
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Dimenhydrinate Inj 10mgLiquid10 mgIntravenousSandoz Canada Incorporated1973-12-31Not applicableCanada
Dimenhydrinate Inj 10mg/mlLiquid10 mgIntravenousAstra Pharma Inc.1986-12-311999-07-29Canada
Dimenhydrinate Inj 50mg USPLiquid50 mgIntramuscular; IntravenousSandoz Canada Incorporated1973-12-31Not applicableCanada
Dimenhydrinate Injection 50mg/mlSolution50 mgIntramuscular; IntravenousAstra Zeneca1986-12-312005-05-31Canada
Dimenhydrinate Injection USPSolution50 mgIntramuscular; IntravenousTeligent Ou2016-01-28Not applicableCanada
Dimenhydrinate Injection USP 250mg/5ml (50mg/ml)Solution50 mgIntramuscular; IntravenousAlveda Pharmaceuticals Inc2008-06-26Not applicableCanada
Dimenhydrinate Injection USP With PreservativeSolution50 mgIntramuscular; IntravenousTeligent Ou2016-01-28Not applicableCanada
Dimenhydrinate Injection, USPSolution50 mgIntramuscular; IntravenousMylan Pharmaceuticals1994-12-31Not applicableCanada
Gravol ImSolution50 mgIntramuscularChurch & Dwight Company, Inc.1953-12-31Not applicableCanada
Gravol IV AmpoulesSolution10 mgIntravenousChurch & Dwight Company, Inc.1953-12-312008-07-30Canada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
DimenhydrinateInjection, solution50 mg/mLIntramuscular; IntravenousAPP Pharmaceuticals, Inc.2004-11-29Not applicableUs
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Airmit AceTablet25 mg/1OralSato Pharmaceutical2005-03-11Not applicableUs
Anti-nauseantTablet50 mgOralApotex Corporation2013-07-02Not applicableCanada
Anti-nauseantTablet50 mgOralPharmascience IncNot applicableNot applicableCanada
Anti-nauseantTablet50 mgOralTevaNot applicableNot applicableCanada
Anti-nauseantTablet50 mgOralVita Health Products Inc2000-05-01Not applicableCanada
Anti-nauseantTablet50 mgOralPharmascience Inc2002-08-23Not applicableCanada
Anti-nauseant TabletTablet50 mgOralStanley Pharmaceuticals, A Division Of Vita Health Products Inc.1998-05-262008-08-07Canada
Apo Dimenhydrinate Tab 50mgTablet50 mgOralApotex Corporation1977-12-31Not applicableCanada
Children's Motion Sickness LiqSolution15 mgOralTanta Pharmaceuticals Inc1996-12-31Not applicableCanada
Children's Motion Sickness LiquidSolution15 mgOralAra Avanti Rx Analytics IncNot applicableNot applicableCanada
Unapproved/Other Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Motion Sickness ReliefTablet50 mg/1OralLnk International, Inc.1992-12-01Not applicableUs
International/Other Brands
Gravol (Church & Dwight) / Vertirosan (Astellas) / Vomex A (Astellas) / Xamamina (Adilna)
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Gravergol CapsulesDimenhydrinate (50 mg) + Caffeine (100 mg) + Ergotamine Tartrate (1 mg)CapsuleOralCan Med Pharma Inc.1957-12-312011-12-07Canada
Categories
UNII
JB937PER5C
CAS number
523-87-5
Weight
Average: 469.964
Monoisotopic: 469.188067494
Chemical Formula
C24H28ClN5O3
InChI Key
DKHVTDUUNTVKOW-UHFFFAOYSA-N
InChI
InChI=1S/C17H21NO.C7H7ClN4O2/c1-18(2)13-14-19-17(15-9-5-3-6-10-15)16-11-7-4-8-12-16;1-11-4-3(9-6(8)10-4)5(13)12(2)7(11)14/h3-12,17H,13-14H2,1-2H3;1-2H3,(H,9,10,13)
IUPAC Name
8-chloro-1,3-dimethyl-2,6-dioxo-2,3,6,7-tetrahydro-1H-purin-7-ide; [2-(diphenylmethoxy)ethyl]dimethylazanium
SMILES
CN1C2=C([N-]C(Cl)=N2)C(=O)N(C)C1=O.C[NH+](C)CCOC(C1=CC=CC=C1)C1=CC=CC=C1

Pharmacology

Indication

Used for treating vertigo, motion sickness, and nausea associated with pregnancy.

Structured Indications
Pharmacodynamics

Dimenhydrinate is an antiemetics drug combination that contains diphenhydramine and theophylline. It is not effective in the treatment of nausea associated with cancer chemotherapy. Dimenhydrinate directly inhibits the stimulation of certain nerves in the brain and inner ear to suppress nausea, vomiting, dizziness, and vertigo. Diphenhydramine and dimenhydinate both reduce vestibular neuronal excitation due to angular or linear acceleration motions.

Mechanism of action

The mechanism by which some antihistamines exert their antiemetic, anti–motion sickness, and antivertigo effects is not precisely known but may be related to their central anticholinergic actions. They diminish vestibular stimulation and depress labyrinthine function. An action on the medullary chemoreceptive trigger zone may also be involved in the antiemetic effect. Dimenhydrinate is a competitive antagonist at the histamine H1 receptor, which is widely distributed in the human brain. Dimenhydrinate's anti-emetic effect is probably due to H1 antagonism in the vestibular system in the brain.

TargetActionsOrganism
AHistamine H1 receptor
antagonist
Human
Absorption

Well absorbed after oral administration.

Volume of distribution
Not Available
Protein binding

98 to 99%.

Metabolism

Hepatic (cytochrome P-450 system).

Route of elimination
Not Available
Half life

1 to 4 hours

Clearance
Not Available
Toxicity

Symptoms of overdose include delerium, hallucinations, and excitment. Patients may be violent and confused.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2,5-Dimethoxy-4-ethylamphetamine2,5-Dimethoxy-4-ethylamphetamine may decrease the sedative activities of Dimenhydrinate.Experimental, Illicit
3,4-Methylenedioxyamphetamine3,4-Methylenedioxyamphetamine may decrease the sedative activities of Dimenhydrinate.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamine4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Dimenhydrinate.Experimental, Illicit
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Dimenhydrinate.Experimental
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Dimenhydrinate.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Dimenhydrinate.Approved
AdipiplonThe risk or severity of adverse effects can be increased when Adipiplon is combined with Dimenhydrinate.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Dimenhydrinate.Approved, Investigational
AlaproclateThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Alaproclate.Experimental
AlfaxaloneThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Dimenhydrinate.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Dimenhydrinate.Approved, Illicit
AllopregnanoloneThe risk or severity of adverse effects can be increased when Allopregnanolone is combined with Dimenhydrinate.Investigational
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Dimenhydrinate.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Alphaprodine is combined with Dimenhydrinate.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Dimenhydrinate.Approved, Illicit, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Amisulpride is combined with Dimenhydrinate.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Dimenhydrinate.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Dimenhydrinate.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Dimenhydrinate.Approved
AmperozideThe risk or severity of adverse effects can be increased when Amperozide is combined with Dimenhydrinate.Experimental
AmphetamineAmphetamine may decrease the sedative activities of Dimenhydrinate.Approved, Illicit
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Dimenhydrinate.Approved, Investigational
ArticaineThe risk or severity of adverse effects can be increased when Articaine is combined with Dimenhydrinate.Approved
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Dimenhydrinate.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Azaperone is combined with Dimenhydrinate.Investigational, Vet Approved
AzelastineDimenhydrinate may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Dimenhydrinate.Approved
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Dimenhydrinate.Illicit
BenperidolThe risk or severity of adverse effects can be increased when Benperidol is combined with Dimenhydrinate.Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Dimenhydrinate.Approved
BenzphetamineBenzphetamine may decrease the sedative activities of Dimenhydrinate.Approved, Illicit
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Dimenhydrinate.Approved
Benzylpenicilloyl PolylysineDimenhydrinate may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
BetahistineThe therapeutic efficacy of Betahistine can be decreased when used in combination with Dimenhydrinate.Approved
BrexpiprazoleThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Brexpiprazole.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Dimenhydrinate.Approved
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Dimenhydrinate.Approved, Illicit
BromisovalThe risk or severity of adverse effects can be increased when Bromisoval is combined with Dimenhydrinate.Experimental
BromperidolThe risk or severity of adverse effects can be increased when Bromperidol is combined with Dimenhydrinate.Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Dimenhydrinate.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Brotizolam is combined with Dimenhydrinate.Approved, Investigational, Withdrawn
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Dimenhydrinate.Approved, Investigational
BuprenorphineDimenhydrinate may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Dimenhydrinate.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Dimenhydrinate.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Butacaine is combined with Dimenhydrinate.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Dimenhydrinate.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Butamben is combined with Dimenhydrinate.Approved
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Dimenhydrinate.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Dimenhydrinate.Approved, Illicit, Vet Approved
CanertinibThe risk or severity of adverse effects can be increased when Canertinib is combined with Dimenhydrinate.Investigational
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Dimenhydrinate.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Dimenhydrinate.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Dimenhydrinate.Illicit, Investigational, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Dimenhydrinate.Approved
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Dimenhydrinate.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Dimenhydrinate.Approved, Illicit, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Dimenhydrinate.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Dimenhydrinate.Approved, Investigational, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Dimenhydrinate.Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Chlorphenamine.Approved
ChlorphentermineChlorphentermine may decrease the sedative activities of Dimenhydrinate.Illicit, Withdrawn
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Dimenhydrinate.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Dimenhydrinate.Approved, Investigational, Withdrawn
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Dimenhydrinate.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Dimenhydrinate.Approved, Vet Approved
CitalopramThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Citalopram.Approved
ClemastineThe risk or severity of adverse effects can be increased when Clemastine is combined with Dimenhydrinate.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Clidinium is combined with Dimenhydrinate.Approved
ClobazamThe risk or severity of adverse effects can be increased when Clobazam is combined with Dimenhydrinate.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when clomethiazole is combined with Dimenhydrinate.Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Clomipramine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Dimenhydrinate.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Clopenthixol is combined with Dimenhydrinate.Experimental
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Dimenhydrinate.Approved, Illicit
ClothiapineThe risk or severity of adverse effects can be increased when Clothiapine is combined with Dimenhydrinate.Experimental
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Dimenhydrinate.Approved
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Dimenhydrinate.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Dimenhydrinate.Approved, Illicit
CyclizineThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Dimenhydrinate.Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Dimenhydrinate.Approved
DantroleneThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Dantrolene.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Dimenhydrinate.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Dapoxetine.Investigational
DeramciclaneThe risk or severity of adverse effects can be increased when Deramciclane is combined with Dimenhydrinate.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Dimenhydrinate.Approved
DesipramineThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Desipramine.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Dimenhydrinate.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Desvenlafaxine.Approved
DetomidineThe risk or severity of adverse effects can be increased when Detomidine is combined with Dimenhydrinate.Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Dimenhydrinate.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Dimenhydrinate.Approved, Vet Approved
DextroamphetamineDextroamphetamine may decrease the sedative activities of Dimenhydrinate.Approved, Illicit
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Dimenhydrinate.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Dimenhydrinate.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Dimenhydrinate.Approved, Investigational
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Dimenhydrinate.Approved, Illicit, Vet Approved
Diethyl etherThe risk or severity of adverse effects can be increased when Diethyl ether is combined with Dimenhydrinate.Experimental
DiethylpropionDiethylpropion may decrease the sedative activities of Dimenhydrinate.Approved, Illicit
DifenoxinThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Difenoxin.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Dimenhydrinate.Approved, Illicit
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Dimenhydrinate.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Dimenhydrinate.Experimental, Illicit
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Dimenhydrinate.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Dimenhydrinate.Approved, Illicit
DixyrazineThe risk or severity of adverse effects can be increased when Dixyrazine is combined with Dimenhydrinate.Experimental
DoramectinThe risk or severity of adverse effects can be increased when Doramectin is combined with Dimenhydrinate.Vet Approved
DoxepinThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Doxepin.Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Dimenhydrinate.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Dimenhydrinate.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Dimenhydrinate.Approved, Illicit
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Dimenhydrinate.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Dimenhydrinate.Experimental, Illicit
DuloxetineThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Dimenhydrinate.Approved
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Dimenhydrinate.Experimental, Illicit
EcopipamThe risk or severity of adverse effects can be increased when Ecopipam is combined with Dimenhydrinate.Investigational
EfavirenzThe risk or severity of adverse effects can be increased when Efavirenz is combined with Dimenhydrinate.Approved, Investigational
EltanoloneThe risk or severity of adverse effects can be increased when Eltanolone is combined with Dimenhydrinate.Investigational
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Dimenhydrinate.Approved, Investigational, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Dimenhydrinate.Approved, Investigational
EscitalopramThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Escitalopram.Approved, Investigational
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Dimenhydrinate.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Dimenhydrinate.Approved
EthanolDimenhydrinate may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Dimenhydrinate.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Dimenhydrinate.Approved
EthotoinThe risk or severity of adverse effects can be increased when Ethotoin is combined with Dimenhydrinate.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Dimenhydrinate.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Ethyl chloride is combined with Dimenhydrinate.Experimental, Investigational
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Dimenhydrinate.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Dimenhydrinate.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Etidocaine is combined with Dimenhydrinate.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Etifoxine is combined with Dimenhydrinate.Investigational, Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Etizolam is combined with Dimenhydrinate.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Dimenhydrinate.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Etoperidone.Withdrawn
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Dimenhydrinate.Illicit, Vet Approved
EzogabineThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Ezogabine.Approved
FelbamateThe risk or severity of adverse effects can be increased when Felbamate is combined with Dimenhydrinate.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Dimenhydrinate.Approved, Illicit, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Dimenhydrinate.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe risk or severity of adverse effects can be increased when Fexofenadine is combined with Dimenhydrinate.Approved
FlibanserinThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Flibanserin.Approved
FluanisoneThe risk or severity of adverse effects can be increased when Fluanisone is combined with Dimenhydrinate.Experimental
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Dimenhydrinate.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Dimenhydrinate.Approved, Illicit
FluoxetineThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Dimenhydrinate.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Dimenhydrinate.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Dimenhydrinate.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Dimenhydrinate.Approved, Investigational
Fluticasone propionateThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Dimenhydrinate.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Dimenhydrinate.Approved, Investigational
FosphenytoinThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Fospropofol is combined with Dimenhydrinate.Approved, Illicit, Investigational
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Dimenhydrinate.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Gabapentin Enacarbil.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Dimenhydrinate.Approved, Illicit, Investigational
GepefrineGepefrine may decrease the sedative activities of Dimenhydrinate.Experimental
GepironeThe risk or severity of adverse effects can be increased when Gepirone is combined with Dimenhydrinate.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Dimenhydrinate.Approved, Illicit
GuanfacineThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Dimenhydrinate.Approved, Illicit, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Dimenhydrinate.Approved
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Dimenhydrinate.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Dimenhydrinate.Approved, Illicit, Investigational
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Dimenhydrinate.Approved
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Dimenhydrinate.Approved, Investigational
HydrocodoneDimenhydrinate may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Dimenhydrinate.Approved, Illicit
HydroxyamphetamineHydroxyamphetamine may decrease the sedative activities of Dimenhydrinate.Approved
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Dimenhydrinate.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Iloperidone.Approved
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Dimenhydrinate.Approved
IndalpineThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Indalpine.Investigational, Withdrawn
IndiplonThe risk or severity of adverse effects can be increased when Indiplon is combined with Dimenhydrinate.Investigational
Iofetamine I-123Iofetamine I-123 may decrease the sedative activities of Dimenhydrinate.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Dimenhydrinate.Approved, Vet Approved
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Dimenhydrinate.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Dimenhydrinate.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Dimenhydrinate.Approved, Investigational
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Dimenhydrinate.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Levetiracetam.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Dimenhydrinate.Approved, Investigational
LevocabastineThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Levocetirizine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Dimenhydrinate.Approved, Investigational
LevomilnacipranThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Levomilnacipran.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Dimenhydrinate.Approved
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Dimenhydrinate.Approved, Vet Approved
LisdexamfetamineLisdexamfetamine may decrease the sedative activities of Dimenhydrinate.Approved, Investigational
LithiumThe risk or severity of adverse effects can be increased when Lithium is combined with Dimenhydrinate.Approved
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Dimenhydrinate.Illicit
LoprazolamThe risk or severity of adverse effects can be increased when Loprazolam is combined with Dimenhydrinate.Experimental
LoratadineThe risk or severity of adverse effects can be increased when Loratadine is combined with Dimenhydrinate.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Dimenhydrinate.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Lormetazepam is combined with Dimenhydrinate.Approved
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Dimenhydrinate.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Dimenhydrinate.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Dimenhydrinate.Approved, Vet Approved
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Dimenhydrinate.Approved
MebicarThe risk or severity of adverse effects can be increased when Mebicar is combined with Dimenhydrinate.Experimental
MeclizineThe risk or severity of adverse effects can be increased when Meclizine is combined with Dimenhydrinate.Approved
MedazepamThe risk or severity of adverse effects can be increased when Medazepam is combined with Dimenhydrinate.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Medetomidine is combined with Dimenhydrinate.Vet Approved
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Dimenhydrinate.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Melperone is combined with Dimenhydrinate.Approved, Investigational
MephedroneMephedrone may decrease the sedative activities of Dimenhydrinate.Investigational
MephentermineMephentermine may decrease the sedative activities of Dimenhydrinate.Approved
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Dimenhydrinate.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Dimenhydrinate.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Meptazinol is combined with Dimenhydrinate.Experimental
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Dimenhydrinate.Approved, Investigational
MetaxaloneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Dimenhydrinate.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Dimenhydrinate.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Dimenhydrinate.Approved, Illicit
MethamphetamineMethamphetamine may decrease the sedative activities of Dimenhydrinate.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Dimenhydrinate.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Dimenhydrinate.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Dimenhydrinate.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Dimenhydrinate.Approved
MethotrimeprazineDimenhydrinate may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Dimenhydrinate.Approved, Investigational, Vet Approved
MethoxyphenamineMethoxyphenamine may decrease the sedative activities of Dimenhydrinate.Experimental
MethsuximideThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Methsuximide.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Dimenhydrinate.Experimental
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Dimenhydrinate.Approved
MetyrosineDimenhydrinate may increase the sedative activities of Metyrosine.Approved
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Dimenhydrinate.Approved, Illicit
MidomafetamineMidomafetamine may decrease the sedative activities of Dimenhydrinate.Experimental, Illicit, Investigational
MilnacipranThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Milnacipran.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Dimenhydrinate.Approved, Investigational
MirtazapineDimenhydrinate may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MMDAMMDA may decrease the sedative activities of Dimenhydrinate.Experimental, Illicit
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with Dimenhydrinate.Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Dimenhydrinate.Approved, Investigational
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Dimenhydrinate.Approved, Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Dimenhydrinate.Approved
NefazodoneThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Nefazodone.Approved, Withdrawn
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Dimenhydrinate.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Dimenhydrinate.Approved, Vet Approved
NorfluraneThe risk or severity of adverse effects can be increased when Norflurane is combined with Dimenhydrinate.Investigational
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Dimenhydrinate.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Dimenhydrinate.Approved
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Dimenhydrinate.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Dimenhydrinate.Approved
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Dimenhydrinate.Approved
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Dimenhydrinate.Approved, Illicit
OrphenadrineDimenhydrinate may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Osanetant is combined with Dimenhydrinate.Investigational
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Dimenhydrinate.Approved
OxethazaineThe risk or severity of adverse effects can be increased when Oxethazaine is combined with Dimenhydrinate.Approved, Investigational
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Dimenhydrinate.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Dimenhydrinate.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Dimenhydrinate.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Dimenhydrinate.Approved, Investigational, Vet Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Dimenhydrinate.Approved
ParaldehydeDimenhydrinate may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved, Investigational
ParoxetineThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Paroxetine.Approved, Investigational
PenfluridolThe risk or severity of adverse effects can be increased when Penfluridol is combined with Dimenhydrinate.Experimental
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Dimenhydrinate.Approved, Vet Approved
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Dimenhydrinate.Approved, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Dimenhydrinate.Approved
PerazineThe risk or severity of adverse effects can be increased when Perazine is combined with Dimenhydrinate.Investigational
PerospironeThe risk or severity of adverse effects can be increased when Perospirone is combined with Dimenhydrinate.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Dimenhydrinate.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Dimenhydrinate.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Phenazocine is combined with Dimenhydrinate.Experimental
PhenibutThe risk or severity of adverse effects can be increased when Phenibut is combined with Dimenhydrinate.Experimental
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Dimenhydrinate.Approved
PhenoperidineThe risk or severity of adverse effects can be increased when Phenoperidine is combined with Dimenhydrinate.Experimental
PhenoxyethanolThe risk or severity of adverse effects can be increased when Phenoxyethanol is combined with Dimenhydrinate.Approved
PhenterminePhentermine may decrease the sedative activities of Dimenhydrinate.Approved, Illicit
PhenytoinThe risk or severity of adverse effects can be increased when Phenytoin is combined with Dimenhydrinate.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Dimenhydrinate.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Dimenhydrinate.Approved, Investigational
PipotiazineThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Pipotiazine.Approved, Investigational
PiritramideThe risk or severity of adverse effects can be increased when Piritramide is combined with Dimenhydrinate.Investigational
PizotifenThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Pizotifen.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Pomalidomide.Approved
PramipexoleDimenhydrinate may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Dimenhydrinate.Approved
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Dimenhydrinate.Approved, Illicit
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Dimenhydrinate.Approved, Illicit, Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Dimenhydrinate.Approved
PrimidoneThe risk or severity of adverse effects can be increased when Primidone is combined with Dimenhydrinate.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Dimenhydrinate.Approved, Investigational, Vet Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Dimenhydrinate.Approved, Vet Approved
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Dimenhydrinate.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Promethazine.Approved
PropanididThe risk or severity of adverse effects can be increased when Propanidid is combined with Dimenhydrinate.Experimental
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Dimenhydrinate.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Dimenhydrinate.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Propoxycaine is combined with Dimenhydrinate.Approved
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Dimenhydrinate.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Proxibarbal is combined with Dimenhydrinate.Experimental
PSD502The risk or severity of adverse effects can be increased when PSD502 is combined with Dimenhydrinate.Investigational
PseudoephedrinePseudoephedrine may decrease the sedative activities of Dimenhydrinate.Approved
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Dimenhydrinate.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Dimenhydrinate.Approved
QuinisocaineThe risk or severity of adverse effects can be increased when Quinisocaine is combined with Dimenhydrinate.Experimental
RacloprideThe risk or severity of adverse effects can be increased when Raclopride is combined with Dimenhydrinate.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Ramelteon is combined with Dimenhydrinate.Approved, Investigational
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Dimenhydrinate.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Dimenhydrinate.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Dimenhydrinate.Approved, Investigational
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Dimenhydrinate.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Ritanserin is combined with Dimenhydrinate.Investigational
RitobegronRitobegron may decrease the sedative activities of Dimenhydrinate.Investigational
RomifidineThe risk or severity of adverse effects can be increased when Romifidine is combined with Dimenhydrinate.Vet Approved
RopiniroleDimenhydrinate may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Dimenhydrinate.Approved
RotigotineDimenhydrinate may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Dimenhydrinate.Approved
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Dimenhydrinate.Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Dimenhydrinate.Approved, Vet Approved
SepranoloneThe risk or severity of adverse effects can be increased when Sepranolone is combined with Dimenhydrinate.Investigational
SertindoleThe risk or severity of adverse effects can be increased when Sertindole is combined with Dimenhydrinate.Approved, Investigational, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Dimenhydrinate.Approved, Vet Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Dimenhydrinate.Approved
StiripentolThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Stiripentol.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Dimenhydrinate.Approved, Investigational
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Dimenhydrinate.Approved, Investigational
SultoprideThe risk or severity of adverse effects can be increased when Sultopride is combined with Dimenhydrinate.Experimental
SuvorexantDimenhydrinate may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TandospironeThe risk or severity of adverse effects can be increased when Tandospirone is combined with Dimenhydrinate.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Dimenhydrinate.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Tasimelteon.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Dimenhydrinate.Approved
TetrabenazineThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Tetrabenazine.Approved
TetracaineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Dimenhydrinate.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Dimenhydrinate.Investigational
TetrodotoxinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Dimenhydrinate.Investigational
ThalidomideDimenhydrinate may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Dimenhydrinate.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Dimenhydrinate.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Dimenhydrinate.Approved, Withdrawn
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Dimenhydrinate.Approved
TiagabineThe risk or severity of adverse effects can be increased when Tiagabine is combined with Dimenhydrinate.Approved
TiaprideThe risk or severity of adverse effects can be increased when Tiapride is combined with Dimenhydrinate.Approved, Investigational
TiletamineThe risk or severity of adverse effects can be increased when Tiletamine is combined with Dimenhydrinate.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Tilidine is combined with Dimenhydrinate.Experimental
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Dimenhydrinate.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Dimenhydrinate.Approved, Withdrawn
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Dimenhydrinate.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Dimenhydrinate.Approved, Investigational
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Dimenhydrinate.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Dimenhydrinate.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Dimenhydrinate.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Dimenhydrinate.Approved
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Tricaine methanesulfonate is combined with Dimenhydrinate.Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Trichloroethylene is combined with Dimenhydrinate.Experimental
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Dimenhydrinate.Approved
TrifluperidolThe risk or severity of adverse effects can be increased when Trifluperidol is combined with Dimenhydrinate.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Dimenhydrinate.Approved, Vet Approved
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Dimenhydrinate.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Dimenhydrinate.Approved
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Dimenhydrinate.Approved, Investigational
VenlafaxineThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Venlafaxine.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Veralipride is combined with Dimenhydrinate.Experimental
VigabatrinThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Vigabatrin.Approved
Vinyl etherThe risk or severity of adverse effects can be increased when Vinyl ether is combined with Dimenhydrinate.Experimental
VortioxetineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Dimenhydrinate.Approved
XenonThe risk or severity of adverse effects can be increased when Xenon is combined with Dimenhydrinate.Experimental
XylazineThe risk or severity of adverse effects can be increased when Xylazine is combined with Dimenhydrinate.Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Dimenhydrinate.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Ziconotide.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Zimelidine.Withdrawn
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Dimenhydrinate.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Zolazepam is combined with Dimenhydrinate.Vet Approved
ZolpidemDimenhydrinate may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Dimenhydrinate.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Dimenhydrinate.Approved
ZotepineThe risk or severity of adverse effects can be increased when Zotepine is combined with Dimenhydrinate.Approved, Investigational
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Dimenhydrinate.Approved, Investigational
Food Interactions
  • Avoid alcohol.
  • Take with food.

References

Synthesis Reference

Cusic, J.W.; U.S. Patent 2,499,058; February 28,1950; assigned to G.D. Searle & Co. Cusic, J.W.; U.S. Patent 2,534,813; December 19,1950; assigned to G.D. Searle & Co.

General References
  1. Takeda N, Morita M, Hasegawa S, Horii A, Kubo T, Matsunaga T: Neuropharmacology of motion sickness and emesis. A review. Acta Otolaryngol Suppl. 1993;501:10-5. [PubMed:8447218]
  2. Halpert AG, Olmstead MC, Beninger RJ: Mechanisms and abuse liability of the anti-histamine dimenhydrinate. Neurosci Biobehav Rev. 2002 Jan;26(1):61-7. [PubMed:11835984]
  3. Jaju BP, Wang SC: Effects of diphenhydramine and dimenhydrinate on vestibular neuronal activity of cat: a search for the locus of their antimotion sickness action. J Pharmacol Exp Ther. 1971 Mar;176(3):718-24. [PubMed:4329456]
External Links
Human Metabolome Database
HMDB15120
KEGG Drug
D00520
PubChem Compound
441281
PubChem Substance
46504881
ChemSpider
10468539
ChEBI
4604
ChEMBL
CHEMBL1200406
Therapeutic Targets Database
DAP000333
PharmGKB
PA449338
Drugs.com
Drugs.com Drug Page
Wikipedia
Dimenhydrinate
ATC Codes
R03DA20 — Combinations of xanthines
AHFS Codes
  • 56:22.08 — Antihistamines
MSDS
Download (72 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2CompletedTreatmentProphylaxis against postoperative nausea and vomiting1
3RecruitingTreatmentVertigo, Peripheral1
4CompletedPreventionProphylaxis against postoperative nausea and vomiting1
4CompletedTreatmentGastroenteritis1
4CompletedTreatmentNausea / Vertigo / Vomiting1
4CompletedTreatmentVertigo, Peripheral1
Not AvailableCompletedTreatmentNausea / Vomiting1

Pharmacoeconomics

Manufacturers
  • App pharmaceuticals llc
  • Baxter healthcare corp anesthesia and critical care
  • Watson laboratories inc
  • Wyeth ayerst laboratories
  • Alra laboratories inc
  • Heather drug co inc
  • Nexgen pharma inc
Packagers
Dosage forms
FormRouteStrength
TabletOral25 mg/1
SolutionOral15 mg
Injection, solutionIntramuscular; Intravenous50 mg/mL
TabletOral50 mg/1
Tablet, film coatedOral50 mg/1
LiquidIntravenous10 mg
LiquidIntramuscular; Intravenous50 mg
SolutionIntramuscular; Intravenous50 mg
LiquidOral15 mg
TabletOral50 mg
TabletOral50.0 mg
Tablet, chewableOral25 mg/1
Tablet, chewableOral50 mg/1
CapsuleOral
Capsule, extended releaseOral75 mg
SuppositoryRectal100 mg
TabletOral15 mg
SolutionIntramuscular50 mg
Tablet, multilayerOral100 mg
SolutionIntravenous10 mg
SuppositoryRectal25 mg
SyrupOral15 mg
Tablet, chewableOral15 mg
Tablet, extended releaseOral75 mg
Tablet, chewableOral50 mg
TabletOral25 mg
CapsuleOral50 mg
Tablet, coatedOral50 mg/1
SyrupOral3 mg
SuppositoryRectal50 mg
Prices
Unit descriptionCostUnit
Dimenhydrinate 50 mg/ml vial5.7USD ml
Dimenhydrinate I.M. 50 mg/ml1.17USD ml
Meclizine 12.5 mg tablet0.62USD tablet
Dramamine less drowsy tablet0.42USD tablet
Dimenhydrinate I.V. 10 mg/ml0.32USD ml
Dramamine 50 mg tablet0.28USD tablet
Novamine 15% iv solution0.09USD ml
Dimenhydrinate 100% powder0.07USD g
Driminate 50 mg tablet0.05USD tablet
Dimenhydrinate 50 mg tablet0.03USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)102.5-104Cusic, J.W.; U.S. Patent 2,499,058; February 28,1950; assigned to G.D. Searle & Co. Cusic, J.W.; U.S. Patent 2,534,813; December 19,1950; assigned to G.D. Searle & Co.
water solubility3000 mg/LMERCK INDEX (1996); approx.
logP-0.39Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00125 mg/mLALOGPS
logP2.67ALOGPS
logP3.65ChemAxon
logS-5.6ALOGPS
pKa (Strongest Basic)8.87ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count1ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area13.67 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity90.94 m3·mol-1ChemAxon
Polarizability30.28 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9975
Blood Brain Barrier+0.8551
Caco-2 permeable+0.5198
P-glycoprotein substrateSubstrate0.7863
P-glycoprotein inhibitor INon-inhibitor0.6923
P-glycoprotein inhibitor IIInhibitor0.6502
Renal organic cation transporterNon-inhibitor0.6507
CYP450 2C9 substrateNon-substrate0.7536
CYP450 2D6 substrateNon-substrate0.8181
CYP450 3A4 substrateSubstrate0.7086
CYP450 1A2 substrateInhibitor0.5287
CYP450 2C9 inhibitorNon-inhibitor0.6308
CYP450 2D6 inhibitorNon-inhibitor0.8589
CYP450 2C19 inhibitorNon-inhibitor0.5817
CYP450 3A4 inhibitorNon-inhibitor0.9028
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.5738
Ames testNon AMES toxic0.5629
CarcinogenicityNon-carcinogens0.7548
BiodegradationNot ready biodegradable0.8211
Rat acute toxicity2.4087 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.5364
hERG inhibition (predictor II)Inhibitor0.5405
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as diphenylmethanes. These are compounds containing a diphenylmethane moiety, which consists of a methane wherein two hydrogen atoms are replaced by two phenyl groups.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Diphenylmethanes
Direct Parent
Diphenylmethanes
Alternative Parents
Xanthines / 6-oxopurines / Alkaloids and derivatives / Benzylethers / Pyrimidones / Aryl chlorides / Vinylogous amides / Heteroaromatic compounds / Imidazoles / Ureas
show 9 more
Substituents
Diphenylmethane / Xanthine / 6-oxopurine / Purinone / Purine / Benzylether / Alkaloid or derivatives / Imidazopyrimidine / Pyrimidone / Aryl chloride
show 26 more
Molecular Framework
Not Available
External Descriptors
organic salt (CHEBI:4604)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Histamine receptor activity
Specific Function
In peripheral tissues, the H1 subclass of histamine receptors mediates the contraction of smooth muscles, increase in capillary permeability due to contraction of terminal venules, and catecholamin...
Gene Name
HRH1
Uniprot ID
P35367
Uniprot Name
Histamine H1 receptor
Molecular Weight
55783.61 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  2. Halpert AG, Olmstead MC, Beninger RJ: Mechanisms and abuse liability of the anti-histamine dimenhydrinate. Neurosci Biobehav Rev. 2002 Jan;26(1):61-7. [PubMed:11835984]

Drug created on June 13, 2005 07:24 / Updated on November 19, 2017 20:34